Holly Maier

TL;DR: The present findings support the efficacy of combined naltrexone/bupropion therapy as an adjunct to intensive BMOD for obesity, and the former had significantly greater improvements in markers of cardiometabolic disease risk.

TL;DR: The greater reduction in body weight was significant as early as week 4, and weight loss continued throughout the study, without evidence of a plateau, which support further development of pramlintide/metreleptin as a novel, integrated neurohormonal approach to obesity pharmacotherapy.

TL;DR: Analytical analyses revealed that food intake suppression with amylin plus PYY[3-36] treatment was synergistic, whereas body weight reduction was additive, and suggest that integrated neurohormonal approaches may hold promise as treatments for obesity.

TL;DR: This work links amylin activation of central neural circuits to these therapeutic effects of pramlintide monotherapy, and speculate on other potential therapeutic applications of amyl in receptor agonism.

TL;DR: Pramlintide treatment is associated with improvements in markers of oxidative stress and cardiovascular risk and improved patient-reported treatment satisfaction, which make pramlintide an attractive option for the treatment of postprandial hyperglycemia in patients with diabetes using mealtime insulin.